跳至主要内容
临床试验/CTRI/2024/11/076617
CTRI/2024/11/076617尚未招募不适用

Evaluation of skin irritation and skin sensitization potential of Moisturex Baby Moisturizing Lotion and Moisturex Baby Shampoo using Human Repeat Insult Patch Test (HRIPT).IS 4011:2018 Guidelines

Sun Pharmaceutical Industries Ltd.1 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2024年11月25日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
220
试验地点
1
主要终点
Evaluation of cutaneous tolerance by dermatological scoring.

研究概览

简要总结

Topical exposure to chemicals can lead to adverse skin effects or skin intolerances.

While some chemicals will only trigger an irritant response after repeated exposure of the same

skin area, other chemicals will even after a one-time exposure cause irritation.

HRIPT is a standard test; usually performed to check the tolerance of a product on skin after

repeated application of those products on the same site.

Sensitization is the process by which a person becomes, over time, increasingly allergic to a

substance through repeated exposure to that substance. It is very different from irritation

because it involves immune response, the reaction becomes worse with repeated exposure, and

it is usually specific to individuals. The HRIPT consists of 2 phases, possibly 3.

Phase I is the Induction Phase where product is applied to the skin 9 times over duration of 3

weeks. This is a followed by rest period of 10- 14 days after which the skin is exposed to the

product again in Phase II or the Elicitation Phase. A response in Phase II is usually allergic in

nature. In some cases when reactions at challenge are weak or do not follow a consistent

pattern, it may be necessary to conduct additional studies on a participant to determine if the

responses are indicative of allergy. This is Phase III of the study- Rechallenge Phase. A

Rechallenge may also be performed to verify that the response is persistent.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Voluntary healthy men and women between 18 and 65 years with at least 50 participants having sensitive skin in the nasolabial area as confirmed by lactic acid sting test @
  • Fitzpatrick skin type III to IV.
  • Having apparently healthy skin on test area.
  • For whom the Investigator considers that the compliance will be correct.
  • Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures.
  • Having signed a Consent Form.
  • Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the study.
  • Willingness to avoid water contact (i.e.: swimming) or activity which cause sweating (i.e.: exercise, sauna etc), during the course of the study.
  • Should be able to read and write (in English, Hindi or local language).
  • Having valid proof of identity and age.

排除标准

  • Pregnancy (by UPT) and lactating women.
  • Scars, excessive terminal hair or tattoo on the studied area.
  • Dermatological infection/pathology on the level of studied area.
  • Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye).
  • Any clinically significant systemic or cutaneous disease, which may interfere with study procedures.
  • Chronic illness which may influence the outcome of the study.
  • Participants on any medical treatment either systemic or topical which may interfere with the performance of the study (presently or in the past 1 month).
  • Participant in an exclusion period or participating in another food, cosmetic or therapeutic trial.

结局指标

主要结局

Evaluation of cutaneous tolerance by dermatological scoring.

时间窗: Visit 1: ICD and inclusion or exclusion. | Induction Phase: Patch application on Visit 1 (V1, V3,V5, V7, V9, V11, V13, V15, V17). | Patch will be removed on Visit 2 (V2, V4, V6, V8, V10, V12,V14, V16, V18). | Patch area will be clinically examined, graded and scored on Visit 3 (V3, V5, V7, V9, V11, V13, V15, V17, V19) | Challenge Phase: Patch application will be on naïve sites on the back on V20; | patch will be removed at V21 (24 hours).Scoring on V22 (48 hours), V23 (72 hours). V24 (96 hours).

次要结局

未报告次要终点

研究者

申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Rajiv Joshi

Clinical Aesthetics and Investigative Management Service Pvt. Ltd. (C.L.A.I.M.S.PVT.LTD.)

研究点 (1)

Loading locations...

相似试验